Multiple Sclerosis Clinical Trial
Official title:
Effects of a 12-week Inspiratory Muscle Training Program With Low Resistance in Patients With Multiple Sclerosis
Objective: To evaluate the effectiveness of a low-intensity protocol of inspiratory muscle
training (IMT) to improve respiratory strength, spirometric parameters and dyspnea in
patients with multiple sclerosis (MS).
Design: Clinical trial. Randomized. Participants: 67 patients with MS, distributed in two
groups, intervention and control.
Intervention: Intervention group train using IMT for 12 weeks, 5 days/week, 15 minutes/day
(20% maximum inspiratory pressure (MIP) during the first two weeks and 30% MIP after the
second week). Control group follow a respiratory exercise program involving nasal breathing
and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
Evaluations: Determination of the MIP and the maximum expiratory pressure (MEP); spirometry -
maximum voluntary ventilation (MVV), peak expiratory flow (PEF), tidal volume (TV); dyspnea
using the Borg scale and clinical evaluations.
Status | Not yet recruiting |
Enrollment | 67 |
Est. completion date | September 15, 2019 |
Est. primary completion date | July 24, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - Diagnosed with MS - Over 18 years old - Disability lower than 9 in the EDSS - Be able to understand the objectives of the study Exclusion criteria: - Participants with a current or past neurological pathology other than MS - Relapse of MS or any respiratory pathology during the 4 weeks prior to the start of the study - Any other complication that may impede the performance of the evaluation tests or breathing techniques |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Salamanca |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximal inspiratory pressure (MIP) | The evaluation is performed using a pressure transducer, Elka 15, which obtainer each measurement in millibar and converted it into the reference unit of centimeter of water (cm H2O) (1 mbar = 1.01973 cm H2O), following the rules of the ATS / ERS. The procedure was repeated until 3 values were obtained with a difference of less than 5%, and the highest value was used for the analysis. The MIP of the intervention group was assessed every 2 weeks to set the IMT workload. | 5 minutes | |
Primary | Maximal expiratory pressure (MEP) | The evaluation is performed using a pressure transducer, Elka 15. It is evaluated at the beginning and at the end of the interventional phase. Measure: cm H20 | 5 minutes | |
Secondary | Dyspnea | Dyspnea is assessed using modified Borg scale. It is a scale between 1-10 points, 1 is the minimum and 10 is the maximum level of dyspnea or fatigue. More punctuation in the scale, more dyspnea. | 1 minute | |
Secondary | Maximum voluntary ventilation (MVV) | Spirometer with a turbine transducer with a maximum flow of 16 l/s and a maximum volume of 10 l. The ATS/ERS rules were followed [19], and the highest value of three correct measurements was chosen. Measure: Liter(L) / minute(m) | 1 minute | |
Secondary | Forced expiratory volume in the first second (FEV1) | Spirometer with a turbine transducer with a maximum flow of 16 l/s and a maximum volume of 10 l. The ATS/ERS rules were followed [19], and the highest value of three correct measurements was chosen. Measure: L | 1 minute | |
Secondary | Peak expiratory flow (PEF) | Spirometer with a turbine transducer with a maximum flow of 16 l/s and a maximum volume of 10 l. The ATS/ERS rules were followed [19], and the highest value of three correct measurements was chosen. Measure: L / second (s) | 1 minute | |
Secondary | Mean expiratory flow (FEF25-75) | Spirometer with a turbine transducer with a maximum flow of 16 l/s and a maximum volume of 10 l. The ATS/ERS rules were followed [19], and the highest value of three correct measurements was chosen. Measure: L / s | 1 minute | |
Secondary | Vital capacity (VC) | Spirometer with a turbine transducer with a maximum flow of 16 l/s and a maximum volume of 10 l. The ATS/ERS rules were followed [19], and the highest value of three correct measurements was chosen. Measure: L | 1 minute | |
Secondary | Tidal volume (VT) | Spirometer with a turbine transducer with a maximum flow of 16 l/s and a maximum volume of 10 l. The ATS/ERS rules were followed [19], and the highest value of three correct measurements was chosen. Measure: L | 1 minute | |
Secondary | Forced vital capacity (FVC) | Spirometer with a turbine transducer with a maximum flow of 16 l/s and a maximum volume of 10 l. The ATS/ERS rules were followed [19], and the highest value of three correct measurements was chosen. Measure: L | 1 minute |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|